Tag Archives: RAD

Top 10 Medical Stocks To Own Right Now

Yesterday, our Under the Radar Moversnewsletter suggested small cap Viveve Medical Inc (NASDAQ: VIVE) as a short/bearish trade:

This downtrend just firmed up with the “second wind” effort evidenced in just the past couple of trading days. After finding support for the better part of September and October, the floor finally broker in late October. A bounce started to take shape in early November, but all it took was a bump into the 20-day moving average line to put the pullback back into motion. Today’s and yesterday’s bar we’ve seen opens and closes at the lower end of the trading range, and so far today we’ve seen a lower low and lower high on very strong selling volume. Let’s just take the hint at face value.

Our Under the Radar Moversnewsletter has a more detailed discussion about Viveve Medicals technical chart along with a potential short/bearish trading strategy:

Top 10 Medical Stocks To Own Right Now: KongZhong Corporation(KZ)

Advisors’ Opinion:

  • [By Monica Gerson]

    The list of below stocks is notable as the shares have traded on sequentially increasing volume spanning the trading days from September 16 to September 20:

Top 10 Medical Stocks To Own Right Now: Best Buy Co., Inc.(BBY)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Then there was Best Buy (BBY) with a surprisingly strong quarter.

    Many of the losers can be found at the mall, with Gap Stores (GPS) and Abercrombie & Fitch (ANF) continuing to disappoint. The only winner at the mall was Childrens’ Place (PLCE) , but Cramer said he’s not counting out a turnaround at L Brands (LB) .

  • [By Peter Graham]

    The Q3 2017 earnings report for large cap consumer electronics retail stock Best Buy Co Inc (NYSE: BBY) is scheduled before the market opens onThursday (November 17th) as a technical chart shows shares still in an apparent uptrend albeit also appearing to have leveled off or be range bound since mid-August:

  • [By Ben Levisohn]

    The folks at Bespoke Investment Group note that its “Death By Amazon” index, which includesBest Buy (BBY), Barnes & Noble (BKS), Wal-Mart Stores (WMT), and Macy’s (M), among other traditional retailers that have been hurt by Amazon.com’s (AMZN) dominance, has been outperforming since Donald Trump’s election victory:

Top 10 Medical Stocks To Own Right Now: BlackRock, Inc.(BLK)

Advisors’ Opinion:

  • [By Shauna O’Brien]

    UBS announced on Wednesday that it has cut its rating on investment management firm BlackRock, Inc. (BLK).

    The firm has downgraded BlackRock from “Buy” to “Neutral” due to expenses, which are putting pressure on margins. UBS also lowered its price target on BLK to $280, which suggests a 5% upside from the stock’s current price of $266.51.

    BlackRock shares were down $2.51, or 0.94%, during pre-market trading Wednesday. The stock is up 29% YTD.

  • [By Tom Aspray, Senior Editor, MoneyShow.com]

    Some of the emerging market ETFs are already up 7%, so far, this month, as it seems like others are drawing the same conclusions. Robert Kapito, co-founder of BackRock, Inc. (BLK), which has assets of $3.9 trillion, said that “The emerging markets are going to account for about 60 to 65% of the world’s growth over the next 20 years.”

Top 10 Medical Stocks To Own Right Now: Vical Incorporated(VICL)

Advisors’ Opinion:

  • [By Lisa Levin]

    Vical Incorporated (NASDAQ: VICL) shares dropped 22 percent to $3.01 after the company disclosed that its Phase 2 trial did not meet primary endpoint.

Top 10 Medical Stocks To Own Right Now: Brown(n)

Advisors’ Opinion:

  • [By Alex Jordon]

    He already owns a good chunk of NetSuite (N), whose revenue grew 35% last quarter, beating earnings estimates by $0.03 a share. Ellison’s been profiting from the cloud while dismissing its significance. With the Salesforce agreement his company is, too. (Fool)

  • [By Arie Goren]

    On November 5, Oracle (NYSE:ORCL)confirmed that it has finally completed the acquisition of Netsuite (NYSE:N) for $9.3 billion in cash, or $109 per share that the company had initially offered. In my previous article about Oracle, I had suggested that the acquisition of NetSuite, the cloud business application software company, is a smart move by Oracle. What’s more, it is not paying an excessive price for the deal. In fact, Oracle insisted that it will not pay more than what it had first offered despite the resistance from T Rowe Price (NSDQ:TROW)which demanded $133 per share.

Top 10 Medical Stocks To Own Right Now: Rite Aid Corporation(RAD)

Advisors’ Opinion:

  • [By Matthew Smith]

    Speaking of subsectors in the retailing industry we are bullish on, how about the drugstores? They all seem to be running on all cylinders and yesterday Rite-Aid (RAD) had a tremendous day. It was the heaviest traded stock on all of the exchanges and saw its shares rise $0.87 (23.45%) to close at $4.58/share. Rite-Aid is the first among the ‘Big Three’ to report quarterly results so we find it interesting that they saw an increase in same store sales and saw profits driven by generic drugs. We have been told that this is going to be the bottom line driver for the industry via nearly everyone and that it would impact the top line as generics replaced the more expensive branded drugs. We care about earnings growth more than revenue growth, especially when the stall in revenues is due to switching to higher margin product which is purchased for a lower price. The market gets this and is pushing all of these names higher. In hindsight we wish we had been more bullish of Rite-A id earlier, but hindsight is always perfect.

  • [By Benzinga News Desk]

    Shares of Rite Aid (NYSE: RAD) surged to a high of $7.89 following a DealReporter story that Walgreens (NASDAQ: WBA) is close to reaching a deal to satisfy the US FTC, which would involve divestiture of up to 1,000 stores. Companies interested in the Walgreen's assets are said to include Kroger, Albertsons, CVS Health, Kinney Drugs and Fred's.

  • [By Teresa Rivas]

    Rite Aid (RAD) was up more than 15% at recent check, near six-year highs, as its second quarter surprised investors with an unexpected profit.

    The drugstore said it earned $32.8 million, or three cents a share, compared with a year-earlier loss of $38.8 million, or a nickel a share. Analysts were looking for a per-share loss of four cents for the period ended August 31.

    Rite Aids total sales climbed 0.8% to $$6.28 billion, while same-store sales rose 1%, as a 0.3% decline in front-end sales was more than offset by a 1.7% increase in pharmacy sales.

    In addition, Rite Aid also increased its forecast, saying it now expects to earn to between 18 cents and 27 cents a share on sales of $25.1 billion to $25.3 billion and same-store sales of plus or minus 0.5%. The companys EPS estimate is above expectations, while the revenue guidance is in-line with current forecasts.

    At recent check, rival Walgreen (WAG), the nations largest chain, was up 0.5%, while CVS Caremark (CVS), the second-largest drugstore operator, was down 0.1%.

  • [By Ben Levisohn]

    Chase announced that the company will process payments for Wal-Mart on the companys closed-loop network, ChaseNet. We would expect the economics of the deal to benefit Wal-Mart and thus the signing of the agreement and onboarding of another payment processor. The real takeaway for us is that today’s announcement adds one of the largest US retailers by revenues to the growing list of merchants that already accept ChaseNet including: Starbucks (SBUX), Marriott (MAR), United (UAL), Rite Aid (RAD), and Chevron (CVX). Thus, JPMorgan is building scale on the company’s platform and that needs to continue longer term.

  • [By Monica Gerson]

    Analysts expect Rite Aid Corporation (NYSE: RAD) to report its quarterly earnings at $0.06 per share on revenue of $8.40 billion. Rite Aid shares gained 0.25 percent to $8.15 in after-hours trading.

Top 10 Medical Stocks To Own Right Now: Citrix Systems Inc.(CTXS)

Advisors’ Opinion:

  • [By Monica Gerson]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday’s regular session.

Top 10 Medical Stocks To Own Right Now: Liberty Global plc(LBTYA)

Advisors’ Opinion:

  • [By Alex Webb]

    Kabel Deutschland is a key part of Vodafones expansion strategy as the carrier looks for ways to boost revenue and lock in customers with Internet and television offers in addition to wireless service. Kabel Deutschland is the biggest cable company in Germany, Vodafones largest market, and had drawn a rival bid from John Malones Liberty Global Plc. (LBTYA)

Top 10 Medical Stocks To Own Right Now: Silver Bay Realty Trust Corp.(SBY)

Advisors’ Opinion:

  • [By Mark Holder]

    Instead of competing in one-off auctions, the traditional method of acquiring homes and the one preferred by Silver Bay Realty Trust (NYSE: SBY  ) (NYSE: SBY  ) (NYSE: SBY  ) and American Homes 4 Rent (NYSE: AMH  ) (NYSE: AMH  ) (NYSE: AMH  ) , the company is obtaining non-performing loans in pools that include thousands of loans. The ultimate outcome of these different models is unknown, but the market hasso far supported Altisource Residential.

Top 10 Medical Stocks To Own Right Now: Potash Corporation of Saskatchewan Inc.(POT)

Advisors’ Opinion:

  • [By Daniela Pylypczak]

    Morgan Stanley announced on Monday that it has resumed coverage on Potash Corp (POT).

    Morgan Stanley analyst Vincent Andrews stated that the company has assigned the fertilizer stock an “Equal Weight” rating, warning “We remain cautious on the overall potash market, though more because of loose supply/demand fundamentals than because of dynamics in Russia/Belorussia. Potash prices have been moving lower for 8 quarters in a row now (7 of which BPC was fully functioning) and prices were continuing to drift lower in the weeks preceding the BPC break-up (recall Mosaic’s disclosure about lower prices in the Brazilian market on its July 16th earnings call.”

    Potash shares popped 1.55% during Monday’s session. Year-to-date, the stock has fallen 21.35%.

  • [By Cameron Swinehart]

    A diversified agriculture ETF with holdings in a variety of the largest agribusiness companies globally. Holdings include Bunge (BG), Archer Daniel Midland (AMD), PotashCorp (POT) and Deere (DE).

  • [By Jon C. Ogg]

    Potash Corp. of Saskatchewan Inc. (NYSE: POT) was up 25 at $33.12 in Monday afternoon trading. Monday’s gain puts shares up within striking distance of its breakout point from the aftermath this summer that took shares from $38 to $31 and ultimately back under $30 before recovering.

  • [By Chad Fraser]

    The agriculture ETF is heavily weighted toward the U.S., with 45.8% of its assets there, but it is geographically diverse, with exposure to countries such as Canada (9.9%), Switzerland (8.5%), Japan (6.7%) and Singapore (5.1%).

    Potash Cartel Breakup Has Weighed on This Agriculture ETF

    The ETF’s unit price declined in the first half of 2013, partly because of the breakup of the Belarusian Potash Company (BPC), through which Russia’s Uralkali, the world’s No. 1 potash producer, and Belaruskali of Belarus distribute their potash. The market is dominated by BPC and Canpotex, owned by Potash Corp. of Saskatchewan (NYSE: POT), Mosaic and Agrium Inc. (NYSE: AGU).

    Together, the two cartels control 70% of global potash exports, so the breakup of BPC will result in a more fractured market, which seems likely to push potash prices lower. Shares of major potash producers fell sharply on the news, as did Market Vectors Agribusiness ETF due to its potash stock holdings, which include Agrium, Potash Corp. and Mosaic.

Is Rite Aid’s Rebound Done for Good?


Can Rite Aid make good on its future hopes? Image source: Rite Aid.

For years, shares of drugstore-chain Rite Aid (NYSE: RAD  ) languished, as many doubted whether the company would ever be able to emerge from its extensive debt and stem its tide of losses. Yet, Rite Aid has defied all of its skeptics during the past two years, becoming consistently profitable and sending shares soaring as much as 750% between late 2012 and early 2014. As impressive as the rebound has been, though, Rite Aid has raised some concerns among long-term investors that its soaring share price might be running out of steam, and the stock has yet to return to its May highs. Now, the big question shareholders want answered is whether Rite Aid can manufacture another leg up in its recovery — or whether its rebound has already given investors everything they should expect.

The rise and fall of Rite Aid
For years, Rite Aid struggled in the drugstore arena, facing the massive challenge of standing up to its two much-larger competitors, Walgreen and CVS, while seeking to strengthen its debt-heavy balance sheet. With a smaller store-network footprint, Rite Aid had to make more from less, and efforts to remodel its stores initially happened at a more sluggish pace than investors wanted to see, reflecting the limitations on capital expenditures that its financial condition warranted.

But Rite Aid benefited from a couple of fortuitous events. First, Walgreen ended its relationship with one of its pharmacy benefits manager partners, effectively driving customers to Rite Aid and other chains. Second, with the extensive patent cliff bringing on a host of higher-margin generic drugs, Rite Aid was able to increase its profits. Moreover, strategic initiatives, such as entering into a supply agreement with major generic drug provider McKesson, reduced the amount of capital Rite Aid needs on hand, as well as potentially gave it even better pricing power and better margins.


Source: Wikimedia Commons.

Just when Rite Aid seemed to have turned the corner for good, though, the company has delivered two disappointing quarters of financial results. In June, Rite Aid told investors that its earnings would take a hit in the then-current quarter and for the full fiscal year; despite the single-penny reduction in earnings per share guidance for fiscal 2015, the stock sank heavily as a result. Then, in September, Rite Aid once again cut its guidance for the full year, reducing earnings per share estimates by 20% to 30%. The company fears that generic drugs won’t provide as much cost savings as Rite Aid had hoped, and pressure on reimbursement rates will also weigh on its bottom line.

Will 2015 bring good times for Rite Aid?
There’s reason to be optimistic about the drugstore chain’s future after solid fiscal third quarter results. Perhaps the most important thing to remember is that Rite Aid’s relationship with its generic-drug distributor is quite new, and the two companies are still working out the kinks in their interactions. Even with outside pressure from temporary delays in generic-drug introductions, the long-term benefits of having higher-margin drug sales should keep lifting Rite Aid’s earnings in future years.

Moreover, demographic trends are still on Rite Aid’s side. As the American population ages, demand for pharmaceuticals is likely to rise, and greater access to healthcare services through government programs could drive even further sales gains for Rite Aid. With its moves to provide more services of its own through its in-store retail clinics, Rite Aid hopes to capture even more of that business than it already does.


Source: Rite Aid.

Still, Rite Aid hasn’t made as much progress in improving the condition of its balance sheet as many investors would like to see. Rite Aid still has far more debt than its major competitors, due in large part to its ill-timed purchase of the Eckerd and Brooks drugstore chains in 2006 right before the housing bust and recession. On the positive side, though, the $6.45 billion in long-term debt that Rite Aid has is actually down more than $1 billion from its peak levels. That’s due, in part, to the availability of positive cash flow, and Rite Aid has done a good job of refinancing its outstanding obligations to reduce interest costs and making the most of its available financial resources.

Rite Aid has made a huge amount of progress in the past two years, and even with its most recent setbacks, the company still appears to be on track with its turnaround efforts. With so much investor pessimism concerning the stock, Rite Aid has the potential to see its share price return to its highs and beyond if it can keep executing on its long-term strategy and get past some of the bumps on the road that it has faced lately.

1 great healthcare stock to buy for 2015 and beyond
Healthcare stocks soared in 2014, and 2015 is shaping up to be another great year for stocks. But if you want to make sure you’re buying one of the best healthcare stocks, you need to know where to start. That’s why The Motley Fool’s chief investment officer just published a brand-new research report that reveals his top stock for the year ahead. To get the full story on this year’s stock — completely free — simply click here.

Stocks Hitting 52-Week Highs

Related AMKR Stocks to Watch for September 12, 2013 Seven Dividend-Paying Tech Stocks Analysts Are Bullish On Related AXAS EXCO Resources to Offer Senior Notes – Analyst Blog Abraxas (AXAS) Shares March Higher, Can It Continue? – Tale of the Tape

Amkor Technology (NASDAQ: AMKR) shares gained 1.63% to touch a new 52-week high of $7.46. Amkor Technology’s PEG ratio is 0.94.

Abraxas Petroleum (NASDAQ: AXAS) shares gained 2.94% to reach a new 52-week high of $4.55. Abraxas Petroleum shares have jumped 93.01% over the past 52 weeks, while the S&P 500 index has gained 17.50% in the same period.

Rite Aid (NYSE: RAD) shares reached a new 52-week high of $7.25 after the company reported better-than-expected fiscal fourth-quarter net income.

Deere & Company (NYSE: DE) shares gained 1.06% to touch a new 52-week high of $94.37. Deere’s trailing-twelve-month ROE is 40.23%.

Posted-In: 52-Week HighsNews Intraday Update Markets Movers

&copy 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  Most Popular UPDATE: Mars to Buy Significant Portion of P&G's Pet Food Unit (Including Iams, Eukanuba, Natura) for $2.9B in Cash; P&G Will Restate Can Marijuana Traders Handle A Stock Meltdown? Stifel Says Buy The Dip In Facebook, RetailMeNot, Netflix, Yahoo! Ahead Of Earnings Biotechs Struggling To Find A Bottom These iPad Air 2 Concepts Are Awesome Bulls In Rackspace Cheer As IBM Takeover Chatter Remains, Analysts Quiet On Rumor Related Articles (AMKR + AXAS) Stocks Hitting 52-Week Highs EXCO Resources to Offer Senior Notes – Analyst Blog Abraxas (AXAS) Shares March Higher, Can It Continue? – Tale of the Tape Chevron: Core Holding in the Integrated Space – Analyst Blog Ultra Petroleum Makes the Right Moves to Hit 52-Week High (Revised) – Analyst Blog Ultra Petroleum Makes the Right Moves to Hit 52-Week High – Analyst Blog